CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 3,673	$ 1,378
Sales and marketing	2,044	43
General and administrative	3,628	1,566
Total operating expenses	9,345	2,987
Loss from operations	(9,345)	(2,987)
Interest expense, net	(317)	(2)
Change in fair value of SAFEs		(2,492)
Loss before benefit from income taxes	(9,662)	(5,481)
Benefit from income taxes		(151)
Net loss	(9,662)	(5,330)
Cumulative preferred dividends allocated to Series A Preferred Shareholders		(388)
Net loss Available to Common Stockholders, basic and diluted	$ (9,662)	$ (5,718)
Net Loss per share attributable to common shareholders, basic and diluted	$ (0.41)	$ (0.54)
Weighted-average shares used in computing net loss per share	23,413,213	10,684,920